Alpha 2.0
Login Register
» Authors » Manuel Battegay

Manuel Battegay

Explore the profile of Manuel Battegay including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 420
Citations 8074
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Microbiology
Top 10 Co-Authors
Enos Bernasconi
Matthias Cavassini
Hansjakob Furrer
Huldrych F Gunthard
Alexandra Calmy
Bernard Hirschel
Pietro Vernazza
Thomas Klimkait
Catia Marzolini
Rainer Weber
Published In
Clin Infect Dis
AIDS
J Infect Dis
Swiss Med Wkly
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure
Berton M, Stader F, Bettonte S, Battegay M, Marzolini C
Open Forum Infect Dis . 2024 Oct; 11(10):ofae585. PMID: 39439743
Background: The World Health Organization is pushing to accelerate the study of new human immunodeficiency virus drugs in pregnant women. However, regulatory guidelines do not specify when to conduct pharmacokinetic...
2.
Secondary attack rate following on-site isolation of patients with suspected COVID-19 in multiple-bed rooms
Ragozzino S, Kuehl R, Leuzinger K, Schlapfer P, Urwyler P, Durovic A, et al.
Antimicrob Resist Infect Control . 2024 Jul; 13(1):73. PMID: 38971822
The implementation of isolation precautions for patients with suspected Coronavirus Disease 2019 (COVID-19) and pending test results is resource intensive. Due to the limited availability of single-bed rooms at our...
3.
Impact of shift work and other work-related factors on anti-SARS-CoV-2 spike-protein serum concentrations in healthcare workers after primary mRNA vaccination - a retrospective cohort study
Menghini G, Thurnheer R, Kahlert C, Kohler P, Grassli F, Stocker R, et al.
Swiss Med Wkly . 2024 Apr; 154:3708. PMID: 38639178
Background: Knowing whether shift work negatively affects the immune system's response to COVID-19 vaccinations could be valuable for planning future vaccination campaigns for healthcare workers. We aimed to determine the...
4.
Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
Bettonte S, Berton M, Stader F, Battegay M, Marzolini C
Open Forum Infect Dis . 2024 Apr; 11(4):ofae171. PMID: 38595957
Background: The life expectancy of people with human immunodeficiency virus (PWH) has significantly increased, thanks to combined antiretrovirals with improved potency and tolerability. One further step has been achieved with...
5.
Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
Bettonte S, Berton M, Battegay M, Stader F, Marzolini C
CPT Pharmacometrics Syst Pharmacol . 2024 Mar; 13(5):781-794. PMID: 38429889
There is growing interest in the use of long-acting (LA) injectable drugs to improve treatment adherence. However, their long elimination half-life complicates the conduct of clinical trials. Physiologically-based pharmacokinetic (PBPK)...
6.
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study
Bettonte S, Berton M, Stader F, Battegay M, Marzolini C
Clin Infect Dis . 2024 Feb; 79(2):477-486. PMID: 38309958
Background: Obesity is increasingly prevalent among people with human immunodeficiency virus (HIV, PWH). Obesity can reduce drug exposure; however, limited data are available for long-acting (LA) antiretrovirals. We performed in...
7.
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study
Abela I, Hauser A, Schwarzmuller M, Pasin C, Kusejko K, Epp S, et al.
J Infect Dis . 2024 Jan; 230(2):e292-e304. PMID: 38227786
Background: Factors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency...
8.
Within-host genetic diversity of extended-spectrum beta-lactamase-producing Enterobacterales in long-term colonized patients
Aguilar-Bultet L, Garcia-Martin A, Vock I, Maurer Pekerman L, Stadler R, Schindler R, et al.
Nat Commun . 2023 Dec; 14(1):8495. PMID: 38129423
Despite recognition of the immediate impact of infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE) on human health, essential aspects of their molecular epidemiology remain under-investigated. This includes knowledge on...
9.
Body mass index trends and its impact of under and overweight on outcome among PLHIV on antiretroviral treatment in rural Tanzania: A prospective cohort study
Kalinjuma A, Hussey H, Mollel G, Letang E, Battegay M, Glass T, et al.
PLoS One . 2023 Aug; 18(8):e0290445. PMID: 37607169
Introduction: Increased body weight is an important risk factor for cardiovascular disease and is increasingly reported as a health problem in people living with HIV (PLHIV). There is limited data...
10.
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Berton M, Bettonte S, Stader F, Decosterd L, Tarr P, Livio F, et al.
Clin Infect Dis . 2023 Aug; 78(1):98-110. PMID: 37602428
Background: Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given...